Michelle Gonzaba

Jan 9, 2025 | myastheniagravisnews.com | Sarah Bendiff |Michelle Gonzaba |Shawna Barnes |Jodi Enders

Traveling was one of my biggest fears after my myasthenia gravis diagnosis in 2019. If I got tired at home easily, what would navigating an airport and exploring a bustling city feel like? A few years ago, when my father suggested my sister and I visit a European country before our Italian visa expired (I will write more about this soon), I chose Paris. Who could resist? Plus, given the historical ties between Algeria, where I live, and France, I’m more familiar with the French system and language.

Nov 14, 2024 | myastheniagravisnews.com | Sarah Bendiff |Michelle Gonzaba |Shawna Barnes

Even though my symptoms started early, I couldn’t make a strategic plan for higher education because I wasn’t diagnosed with myasthenia gravis (MG) until my second year of college. I’d chosen my dream career: physics. You might think of Stephen Hawking as the perfect example of a disabled person in physics, but eight years ago, without a diagnosis, I had no proof of my condition to show the university. That meant I couldn’t access any of the few adjustments offered to disabled students.

Sep 24, 2024 | myastheniagravisnews.com | Andrea Lobo |Katherine Poinsatte |Michelle Gonzaba |Steve Bryson

Blood levels of specific antibodies that target the muscle-specific tyrosine kinase (MuSK) may be biomarkers of disease severity and treatment response in people with myasthenia gravis (MG) who are positive for anti-MuSK antibodies. A study finds that high levels of MuSK-IgG4 — an anti-MuSK antibody subclass – were associated with more severe disease, while reducing it was linked to a favorable response to treatment.

Apr 4, 2024 | myastheniagravisnews.com | Lindsey Shapiro |Patricia Inacio |Vanda Pinto |Michelle Gonzaba

No significant differences in clinical outcomes or quality of life were observed between myasthenia gravis (MG) patients treated with azathioprine or mycophenolate mofetil (MMF), results from the PROMISE-MG observational study show.

Apr 2, 2024 | myastheniagravisnews.com | Andrea Lobo |Patricia Inacio |Michelle Gonzaba |Margarida Maia

Timely rescue therapy use during a myasthenic crisis — a life-threatening complication of myasthenia gravis (MG) marked by severe breathing problems — can reduce mortality among patients. That’s according to new findings from researchers in China, who investigated risk factors associated with prolonged mechanical ventilation, which is commonly required for people with MG who experience a myasthenic crisis.